logo
logo

Benchling Raises $50M Series D To Accelerate Biotech Revolution

May 28, 2020•about 5 years ago

Amount Raised

$50 Million

Round Type

series d

San FranciscoScience And EngineeringSoftware

Description

Benchling, the leading life sciences R&D cloud platform, announced it closed $50 million in Series D funding led by Alkeon and joined by new investors Spark Capital, Lux Capital and ICONIQ Partners, as well as existing investors Thrive Capital and Benchmark. The round comes at one of the most pivotal moments for the biotechnology industry as companies race to deliver diagnostics, therapeutics and vaccines for COVID-19, while advances such as CRISPR and lab robotics continue to fuel breakthroughs in medicine, food and agriculture, energy and materials. Benchling will use the investment to build advanced product capabilities, expand its international presence, and drive adoption across leading R&D organizations, bringing the power of modern-day software to drive the rapid transformation of the life sciences industry.

Company Information

Company

Benchling

Location

San Francisco, California, United States

About

Benchling is the pioneer of the R&D Cloud, software that powers the biotechnology industry. More than 200,000 scientists at over 700 companies and 7,000 research institutions globally have adopted Benchling's R&D Cloud to make breakthrough discoveries and bring the next generation of medicines, food, and materials to market faster than ever before. The R&D Cloud helps these organizations modernize their scientific processes and accelerate collaboration so they can convert the complexity of biology into world-changing results. For more, please visit Benchling.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People